Clinical trial
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
NCT00071812 is registered in ClinicalTrials.gov with Human Genome Sciences Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
- Lead sponsor
- Human Genome Sciences Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2003
- Completion date
- December 31, 2005
- Enrollment
- 283 (actual)
- Sites
- 63
Conditions
As the registry lists them; a condition with its own page is linked.